ArticleThoracic cancer2025

Comparative Efficacy of PD-1 Inhibitor-Based Neoadjuvant Chemoimmunotherapy Regimens for Resectable Stage II-IIIa NSCLC: A Real-World Retrospective Study.

Bo Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.